The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Treatment strategies for multiple sclerosis: When to start, when to change, when to stop?
Open accessAbstract
Multiple sclerosis (MS) is a chronic inflammatory condition of the central nervous system determined by a presumed autoimmune process mainly directed against myelin components but also involving axons and neurons. Acute demyelination shows as clinical relapses that may fully or partially resolve, while chronic demyelination and neuroaxonal injury lead to persistent and irreversible neurological symptoms, often progressing over time. Currently approved disease-modifying therapies are immunomodulatory or immunosuppressive drugs that significantly although variably reduce the frequency of attacks of the relapsing forms of the disease. However, they have limited efficacy in preventing the transition to the progressive phase of MS and are of no benefit after it has started. It is therefore likely that the potential advantage of a given treatment is condensed in a relatively limited window of opportunity for each patient, depending on individual characteristics and disease stage, most frequently but not necessarily in the early phase of the disease. In addition, a sizable proportion of patients with MS may have a very mild clinical course not requiring a disease-modifying therapy. Finally, individual response to existing therapies for MS varies significantly across subjects and the risk of serious adverse events remains an issue, particularly for the newest agents. The present review is aimed at critically describing current treatment strategies for MS with a particular focus on the decision of starting, switching and stopping commercially available immunomodulatory and immunosuppressive therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria
Polman, C. H., Reingold, S. C., Banwell, B., Clanet, M., Cohen, J. A., Filippi, M., Fujihara, K., Havrdova, E., Hutchinson, M., Kappos, L., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22366 · Cited by 9,802
New Multiple Sclerosis Phenotypic Classification
Lublin, F. D. (2014) · European Neurology · doi:10.1159/000367614 · Cited by 4,259
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Polman, C. H., O'Connor, P. W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., Phillips, J. T., Lublin, F. D., Giovannoni, G., Wajgt, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044397 · Cited by 3,386
Defining the clinical course of multiple sclerosis: The 2013 revisions
Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sørensen, P. S., Thompson, A. J., Wolinsky, J. S., Balcer, L. J., Banwell, B., Barkhof, F., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000560 · Cited by 3,177
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Kappos, L., Radue, E.-W., O'Connor, P., Polman, C., Hohlfeld, R., Calabresi, P., Selmaj, K., Agoropoulou, C., Leyk, M., Zhang-Auberson, L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909494 · Cited by 2,644
Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis
Jacobs, L. D., Cookfair, D. L., Rudick, R. A., Herndon, R. M., Richert, J. R., Salazar, A. M., Fischer, J. S., Goodkin, D. E., Granger, C. V., Simon, J. H., et al. (1996) · Annals of Neurology · doi:10.1002/ana.410390304 · Cited by 2,450
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Cohen, J. A., Barkhof, F., Comi, G., Hartung, H.-P., Khatri, B. O., Montalban, X., Pelletier, J., Capra, R., Gallo, P., Izquierdo, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907839 · Cited by 2,204
The IFNB Multiple Sclerosis Study Group (1993) · Neurology · doi:10.1212/wnl.43.4.655 · Cited by 2,085
Ebers, G. C. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03334-0 · Cited by 2,073
Paty, D. W., Li, D. K. B., the UBC MS/MRI Study Group, & the IFNB Multiple Sclerosis Study Group (1993) · Neurology · doi:10.1212/wnl.43.4.662 · Cited by 1,967
Johnson, K. P., Brooks, B. R., Cohen, J. A., Ford, C. C., Goldstein, J., Lisak, R. P., Myers, L. W., Panitch, H. S., Rose, J. W., Schiffer, R. B., et al. (1995) · Neurology · doi:10.1212/wnl.45.7.1268 · Cited by 1,898
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
Gold, R., Kappos, L., Arnold, D. L., Bar-Or, A., Giovannoni, G., Selmaj, K., Tornatore, C., Sweetser, M. T., Yang, M., Sheikh, S. I., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114287 · Cited by 1,733
Jacobs, L. D., Beck, R. W., Simon, J. H., Kinkel, R. P., Brownscheidle, C. M., Murray, T. J., Simonian, N. A., Slasor, P. J., & Sandrock, A. W. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431301 · Cited by 1,501
Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
Fox, R. J., Miller, D. H., Phillips, J. T., Hutchinson, M., Havrdova, E., Kita, M., Yang, M., Raghupathi, K., Novas, M., Sweetser, M. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206328 · Cited by 1,355
Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis
Rudick, R. A., Stuart, W. H., Calabresi, P. A., Confavreux, C., Galetta, S. L., Radue, E.-W., Lublin, F. D., Weinstock-Guttman, B., Wynn, D. R., Lynn, F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044396 · Cited by 1,344
Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
Bloomgren, G., Richman, S., Hotermans, C., Subramanyam, M., Goelz, S., Natarajan, A., Lee, S., Plavina, T., Scanlon, J. V., Sandrock, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1107829 · Cited by 1,242
Cohen, J. A., Coles, A. J., Arnold, D. L., Confavreux, C., Fox, E. J., Hartung, H.-P., Havrdova, E., Selmaj, K. W., Weiner, H. L., Fisher, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61769-3 · Cited by 1,205
Coles, A. J., Twyman, C. L., Arnold, D. L., Cohen, J. A., Confavreux, C., Fox, E. J., Hartung, H.-P., Havrdova, E., Selmaj, K. W., Weiner, H. L., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61768-1 · Cited by 1,198
Girard, M., Duquette, P., & Sibley, W. A. (1993) · Cited by 1,196
Comi, G., Filippi, M., Barkhof, F., Durelli, L., Edan, G., Fernández, O., Hartung, H.-P., Seeldrayers, P., Sørensen, P. S., Rovaris, M., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04725-5 · Cited by 1,053
Multiple Sclerosis: Current Knowledge and Future Outlook
Kamm, C. P., Uitdehaag, B. M., & Polman, C. H. (2014) · European Neurology · doi:10.1159/000360528 · Cited by 1,010
Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
O'Connor, P., Wolinsky, J. S., Confavreux, C., Comi, G., Kappos, L., Olsson, T. P., Benzerdjeb, H., Truffinet, P., Wang, L., Miller, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014656 · Cited by 990
Calabresi, P. A., Radue, E.-W., Goodin, D., Jeffery, D., Rammohan, K. W., Reder, A. T., Vollmer, T., Agius, M. A., Kappos, L., Stites, T., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70049-3 · Cited by 825
Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis
Simpson, S., Blizzard, L., Otahal, P., Van der Mei, I., & Taylor, B. (2011) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2011.240432 · Cited by 718
Comi, G., Filippi, M., & Wolinsky, J. S. (2001) · PubMed · Cited by 688
Kappos, L., Polman, C. H., Freedman, M. S., Edan, G., Hartung, H. P., Miller, D. H., Montalban, X., Barkhof, F., Bauer, L., Jakobs, P., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000237641.33768.8d · Cited by 681
Comi, G., Filippi, M., Wolinsky, J. S., & European/Canadian Glatiramer Acetate Study Group (2001) · Annals of Neurology · doi:10.1002/ana.64 · Cited by 650
Randomized, comparative study of interferon β-1a treatment regimens in MS: The EVIDENCE Trial
Panitch, H., Goodin, D. S., Francis, G., Chang, P., Coyle, P. K., O’Connor, P., Monaghan, E., Li, D., & Weinshenker, B. (2002) · Neurology · doi:10.1212/01.wnl.0000034080.43681.da · Cited by 635
Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis
Friese, M. A., Schattling, B., & Fugger, L. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.37 · Cited by 628
Comi, G., Martinelli, V, Rodegher, M., Moiola, L., Bajenaru, O., Carra, A., Elovaara, I., Fazekas, F., Hartung, H., Hillert, J., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61259-9 · Cited by 592
Confavreux, C., O'Connor, P., Comi, G., Freedman, M. S., Miller, A. E., Olsson, T. P., Wolinsky, J. S., Bagulho, T., Delhay, J.-L., Dukovic, D., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70308-9 · Cited by 579
Kappos, L., Polman, C. H., Freedman, M. S., Edan, G., Hartung, H. P., Miller, D. H., Montalban, X., Barkhof, F., Bauer, L., Jakobs, P., et al. (2007) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2006.11.003 · Cited by 549
Durelli, L., Verdun, E., Barbero, P., Bergui, M., Versino, E., Ghezzi, A., Montanari, E., & Zaffaroni, M. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08430-1 · Cited by 547
Mikol, D. D., Barkhof, F., Chang, P., Coyle, P. K., Jeffery, D. R., Schwid, S. R., Stubinski, B., & Uitdehaag, B. M. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70200-x · Cited by 486
Wolinsky, J. S., Narayana, P. A., O'Connor, P., Coyle, P. K., Ford, C., Johnson, K., Miller, A., Pardo, L., Kadosh, S., Ladkani, D., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21079 · Cited by 429
Multiple Sclerosis: Current and Emerging Disease-Modifying Therapies and Treatment Strategies
Wingerchuk, D. M., & Carter, J. L. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.11.002 · Cited by 416
O'Connor, P., Filippi, M., Arnason, B., Comi, G., Cook, S., Goodin, D., Hartung, H.-P., Jeffery, D., Kappos, L., Boateng, F., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70226-1 · Cited by 405
Vermersch, P., Czlonkowska, A., Grimaldi, L. M., Confavreux, C., Comi, G., Kappos, L., Olsson, T. P., Benamor, M., Bauer, D., Truffinet, P., et al. (2014) · Multiple Sclerosis Journal · doi:10.1177/1352458513507821 · Cited by 354
Pathology of multiple sclerosis and related inflammatory demyelinating diseases
(2014) · Handbook of Clinical Neurology · doi:10.1016/b978-0-444-52001-2.00002-9 · Cited by 303
Miller, A. E., Wolinsky, J. S., Kappos, L., Comi, G., Freedman, M. S., Olsson, T. P., Bauer, D., Benamor, M., Truffinet, P., & O'Connor, P. W. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70191-7 · Cited by 300
Incidence of multiple sclerosis in multiple racial and ethnic groups
Langer-Gould, A., Brara, S. M., Beaber, B. E., & Zhang, J. L. (2013) · Neurology · doi:10.1212/wnl.0b013e3182918cc2 · Cited by 299
MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials
Sormani, M. P., & Bruzzi, P. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70103-0 · Cited by 278
Scoring treatment response in patients with relapsing multiple sclerosis
Sormani, M., Rio, J., Tintorè, M., Signori, A., Li, D., Cornelisse, P., Stubinski, B., Stromillo, M., Montalban, X., & De Stefano, N. (2013) · Multiple Sclerosis Journal · doi:10.1177/1352458512460605 · Cited by 262
The clinical course of multiple sclerosis
(2014) · Handbook of Clinical Neurology · doi:10.1016/b978-0-444-52001-2.00014-5 · Cited by 231
Incidence and Prevalence of Multiple Sclerosis in the Americas: A Systematic Review
Evans, C., Beland, S.-G., Kulaga, S., Wolfson, C., Kingwell, E., Marriott, J., Koch, M., Makhani, N., Morrow, S., Fisk, J., et al. (2013) · Neuroepidemiology · doi:10.1159/000342779 · Cited by 211
MRI T2 lesion burden in multiple sclerosis: A plateauing relationship with clinical disability
Li, D. K. B., Held, U., Petkau, J., Daumer, M., Barkhof, F., Fazekas, F., Frank, J. A., Kappos, L., Miller, D. H., Simon, J. H., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000210506.00078.5c · Cited by 208
Menzin, J., Caon, C., Nichols, C., White, L. A., Friedman, M., & Pill, M. W. (2013) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2013.19.s1.s24 · Cited by 204
Risk of cancer from azathioprine therapy in multiple sclerosis: A case-control study
Confavreux, C., Saddier, P., Grimaud, J., Moreau, T., Adeleine, P., & Aimard, G. (1996) · Neurology · doi:10.1212/wnl.46.6.1607 · Cited by 203
Treatment Optimization in MS: Canadian MS Working Group Updated Recommendations
Freedman, M. S., Selchen, D., Arnold, D. L., Prat, A., Banwell, B., Yeung, M., Morgenthau, D., & Lapierre, Y. (2013) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100014244 · Cited by 202
Polman, C. H., Bertolotto, A., Deisenhammer, F., Giovannoni, G., Hartung, H.-P., Hemmer, B., Killestein, J., McFarland, H. F., Oger, J., Pachner, A. R., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70103-4 · Cited by 198
The epidemiology of multiple sclerosis
(2014) · Handbook of Clinical Neurology · doi:10.1016/b978-0-444-52001-2.00010-8 · Cited by 190
Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis
Filippini, G., Del Giovane, C., Vacchi, L., D'Amico, R., Di Pietrantonj, C., Beecher, D., & Salanti, G. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008933.pub2 · Cited by 186
Cadavid, D., Wolansky, L. J., Skurnick, J., Lincoln, J., Cheriyan, J., Szczepanowski, K., Kamin, S. S., Pachner, A. R., Halper, J., & Cook, S. D. (2009) · Neurology · doi:10.1212/01.wnl.0000345970.73354.17 · Cited by 185
PML in a Patient Treated with Dimethyl Fumarate from a Compounding Pharmacy
van Oosten, B. W., Killestein, J., Barkhof, F., Polman, C. H., & Wattjes, M. P. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1215357 · Cited by 185
Mitoxantrone for multiple sclerosis
Boneschi, F. M., Vacchi, L., Rovaris, M., Capra, R., & Comi, G. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002127.pub3 · Cited by 183
Arvin, A. M., Wolinsky, J. S., Kappos, L., Morris, M. I., Reder, A. T., Tornatore, C., Gershon, A., Gershon, M., Levin, M. J., Bezuidenhoudt, M., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.3065 · Cited by 182
Management of Multiple Sclerosis During Pregnancy and the Reproductive Years: A Systematic Review
Bove, R. M., Alwan, S. S., Friedman, J. M., Hellwig, K., Houtchens, M. K., Koren, G., Lu, E., McElrath, T. F., Smyth, P. S., Tremlett, H. L., et al. (2014) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000000541 · Cited by 151
Azathioprine for multiple sclerosis
Casetta, I., Iuliano, G., & Filippini, G. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003982.pub2 · Cited by 150
Switching From Natalizumab to Fingolimod in Multiple Sclerosis: A French Prospective Study
Cohen, M., Maillart, É., Tourbah, A., Seze, J. D., Vukusic, S., Brassat, D., Anne, O., Wiertlewski, S., Camu, W., Courtois, S., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.6240 · Cited by 145
Fingolimod after natalizumab and the risk of short-term relapse
Jokubaitis, V., Li, V., Kalinčík, T., Izquierdo, G., Hodgkinson, S. J., Alroughani, R., Lechner‐Scott, J., Lugaresi, A., Duquette, P., Girard, M., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000283 · Cited by 142
Koch, M. W., Mostert, J. P., de Vries, J. J., & Keyser, J. D. (2007) · Neurology · doi:10.1212/01.wnl.0000261131.23708.1c · Cited by 129
Vennegoor, A., Rispens, T., Strijbis, E. M. M., Seewann, A., Uitdehaag, B. M. J., Balk, L. J., Barkhof, F., Polman, C. H., Wolbink, G., & Killestein, J. (2012) · Multiple Sclerosis Journal · doi:10.1177/1352458512460604 · Cited by 126
Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis
Sormani, M. P., Li, D. K., Bruzzi, P., Stubinski, B., Cornelisse, P., Rocak, S., & Stefano, N. D. (2011) · Neurology · doi:10.1212/wnl.0b013e31823648b9 · Cited by 114
MRI as an outcome in multiple sclerosis clinical trials
Däumer, M., Neuhaus, A. A., Morrissey, S., Hintzen, R. Q., & Ebers, G. C. (2008) · Neurology · doi:10.1212/01.wnl.0000336916.38629.43 · Cited by 114
Assessing changes in relapse rates in multiple sclerosis
Inusah, S., Sormani, M. P., Cofield, S. S., Aban, I., Musani, S. K., Srinivasasainagendra, V., & Cutter, G. (2010) · Multiple Sclerosis Journal · doi:10.1177/1352458510379246 · Cited by 113
New management algorithms in multiple sclerosis
Sørensen, P. S. (2014) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000096 · Cited by 108
Gajofatto, A., Bacchetti, P., Grimes, B. A., High, A. S., & Waubant, E. L. (2008) · Multiple Sclerosis Journal · doi:10.1177/1352458508096687 · Cited by 99
Self-citationKinkel, R. P., Dontchev, M., Kollman, C., Skaramagas, T. T., O'Connor, P. W., & Simon, J. H. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.1426 · Cited by 97
Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome
Comi, G., Martinelli, V., Rodegher, M., Moiola, L., Leocani, L., Bajenaru, O. A., Carrá, A., Elovaara, I., Fazekas, F., Hartung, H.-P., et al. (2012) · Multiple Sclerosis Journal · doi:10.1177/1352458512469695 · Cited by 93
Edan, G., Comı, G., Page, E. L., Leray, E., Rocca, M. A., Filippi, M., & for The French-Italian Mitoxantrone Interferon-beta-1b Trial Group (2011) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2010.229724 · Cited by 93
MRI ASANOUTCOMEIN MULTIPLE SCLEROSIS CLINICAL TRIALS
Sormani, M. P., Filippi, M., Stefano, N. D., Ebers, G., & Daumer, M. (2009) · Neurology · doi:10.1212/wnl.0b013e3181bd6b8f · Cited by 91
Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis
Mantia, L. L., Pietrantonj, C. D., Rovaris, M., Rigon, G., Frau, S., Berardo, F., Gandini, A., Longobardi, A., Weinstock‐Guttman, B., & Vaona, A. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009333.pub3 · Cited by 86
Interferon Beta for Primary Progressive Multiple Sclerosis
Rojas, J. I., Romano, M., Ciapponi, A., Patrucco, L., & Cristiano, E. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006643.pub3 · Cited by 86
Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT
Edan, G., Kappos, L., Montalbán, X., Polman, C. H., Freedman, M. S., Hartung, H., Miller, D., Barkhof, F., Herrmann, J., Lanius, V., et al. (2013) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2013-306222 · Cited by 84
Requirement for safety monitoring for approved multiple sclerosis therapies: an overview
Rommer, P. S., Zettl, U. K., Kieseier, B. C., Hartung, H.-P., Menge, T., Frohman, E. M., Greenberg, B. M., Hemmer, B., & Stüve, O. (2013) · Clinical & Experimental Immunology · doi:10.1111/cei.12206 · Cited by 80
Cancer and multiple sclerosis in the era of disease-modifying treatments
Lebrun‐Frénay, C., Vermersch, P., Brassat, D., Defer, G. L., Rumbach, L., Clavelou, P., Debouverie, M., Seze, J. D., Wiertlewski, S., Heinzlef, O., et al. (2011) · Journal of Neurology · doi:10.1007/s00415-011-5929-9 · Cited by 72
Not Every Patient With Multiple Sclerosis Should Be Treated at Time of Diagnosis
Pittock, S. J., Weinshenker, B. G., Noseworthy, J. H., Lucchinetti, C. F., Keegan, M., Wingerchuk, D. M., Carter, J., Shuster, E. A., & Rodriguez, M. (2006) · Archives of Neurology · doi:10.1001/archneur.63.4.611 · Cited by 62
Massacesi, L., Tramacere, I., Amoroso, S., Battaglia, M. A., Benedetti, M. D., Filippini, G., Mantia, L. L., Repice, A. M., Solari, A., Tedeschi, G., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113371 · Cited by 61
Self-citationAzathioprine for multiple sclerosis
Casetta, I., Iuliano, G., & Filippini, G. (2009) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.144972 · Cited by 59
Fostering adherence to injectable disease-modifying therapies in multiple sclerosis
Lugaresi, A., Rottoli, M. R., & Patti, F. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.945523 · Cited by 59
Update on Disease-Modifying Treatments for Multiple Sclerosis
Carrithers, M. D. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.08.006 · Cited by 55
The current role of mitoxantrone in the treatment of multiple sclerosis
Cocco, E. E., & Marrosu, M. G. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.915742 · Cited by 46
Miller, D. M., Rudick, R. A., & Hutchinson, M. (2010) · Neurology · doi:10.1212/wnl.0b013e3181dbb884 · Cited by 46
Evans, C. D., Tam, J., Kingwell, E., Oger, J., & Tremlett, H. L. (2012) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.01.006 · Cited by 43
A reassessment of the plateauing relationship between T2 lesion load and disability in MS
Sormani, M. P., Rovaris, M., Comi, G., & Filippi, M. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c06679 · Cited by 41
Ziemssen, T., Bajenaru, O. A., Carrá, A., Klippel, N. D., de Sá, J. C., Edland, A., Frederiksen, J. L., Heinzlef, O., Karageorgiou, K. E., Delgado, R. H. L., et al. (2014) · Journal of Neurology · doi:10.1007/s00415-014-7446-0 · Cited by 41
Río, J., Rovira, À., Tintoré, M., Sastre‐Garriga, J., Castilló, J., Auger, C., Nos, C., Comabella, M., Tur, C., Vidal‐Jordana, Á., et al. (2014) · Multiple Sclerosis Journal · doi:10.1177/1352458514527863 · Cited by 41
Stoppers and non-starters of disease-modifying treatment in multiple sclerosis
Grytten, N., Aarseth, J. H., Espeset, K., Johnsen, G., Wehus, R., Lund, C., & Haugstad, R. (2012) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2012.01708.x · Cited by 33
Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis
Mantia, L. L., Pietrantonj, C. D., Rovaris, M., Rigon, G., Frau, S., Berardo, F., Gandini, A., Longobardi, A., Weinstock‐Guttman, B., & Vaona, A. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009333.pub2 · Cited by 23
Cited by
Review of multiple sclerosis: Epidemiology, etiology, pathophysiology, and treatment
Haki, M., AL-Biati, H. A., Al-Tameemi, Z. S., Ali, I. S., & Al-hussaniy, H. A. (2024) · Medicine · doi:10.1097/md.0000000000037297 · Cited by 274
GANAB as a Novel Biomarker in Multiple Sclerosis: Correlation with Neuroinflammation and IFI35
De Masi, R., & Orlando, S. (2021) · Pharmaceuticals · doi:10.3390/ph14111195 · Cited by 10
“Despite the many studies suggesting the critical role of peripheral autoreactive T-cells in the demyelination process and axonal loss [1], there is still no usable cell-based biomarker of disease activity [2,3].”
Background
Metadata
- Authors
- Gajofatto, A., & Benedetti, M. D.
- Venue
- World Journal of Clinical Cases
- Publisher
- Baishideng Publishing Group Inc.
- Published
- 2015
- Volume
- 3
- Issue
- 7
- Pages
- 545
- ISSN
- 2307-8960 (ISSN-L)
- OpenAlex
- W1573130413
- Cited by
- 256
- References
- 90
- FWCI
- 12.62
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.